TIOCONAZOLE
Clinical safety rating: safe
Animal studies have demonstrated safety
Inhibition of fungal CYP450-dependent 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
| Metabolism | Minimal systemic absorption; not extensively metabolized. |
| Excretion | Primarily fecal (minimally absorbed; <5% absorbed dose excreted renally as metabolites); topically applied tioconazole is largely unabsorbed. |
| Half-life | Terminal elimination half-life is approximately 24–30 hours after topical application, reflecting slow systemic clearance of absorbed fraction. |
| Protein binding | Approximately 90–95% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Not well characterized due to minimal systemic absorption; estimated Vd <0.1 L/kg after topical application, indicating limited distribution. |
| Bioavailability | Topical vaginal: <5% of dose absorbed systemically; oral bioavailability negligible (<1%) due to extensive first-pass metabolism. |
| Onset of Action | Topical: Clinical improvement (relief of symptoms) typically begins within 24–72 hours; antifungal effect begins immediately upon contact. |
| Duration of Action | Topical: After single application, therapeutic concentrations persist in vaginal mucosa for 48–72 hours; clinical cure usually requires 7–14 days of daily application. |
| Molecular Weight | 387.72 |
Topical: Apply 1% cream, lotion, or solution to affected area twice daily for 2-4 weeks. Vaginal: Insert 1 applicatorful of 6.5% ointment intravaginally at bedtime as a single dose.
| Dosage form | OINTMENT |
| Renal impairment | No dose adjustment required for topical use; systemic absorption minimal. For systemic use, no specific GFR-based guidelines exist; use caution in severe renal impairment. |
| Liver impairment | No dose adjustment required for topical use. For systemic use, contraindicated in Child-Pugh Class C; reduce dose by 50% in Child-Pugh Class B (if oral formulation available). |
| Pediatric use | Topical: Apply to affected area twice daily for 2-4 weeks in children ≥2 years. Safety in infants <2 years not established. |
| Geriatric use | No specific dose adjustment required for topical use; monitor for local irritation. For vaginal use, same as adult dosing. |
| 1st trimester | Limited human data; animal studies not available; no known teratogenicity; avoid unless benefit outweighs risk. |
| 2nd trimester | Topical use considered safe; systemic absorption minimal; no reported adverse fetal effects. |
| 3rd trimester | Topical use considered safe; systemic absorption minimal; no reported adverse fetal effects. |
Clinical note
No significant drug interactions For topical use only not for ophthalmic use.
| Placental transfer | Minimal placental transfer expected due to low systemic absorption after topical administration; no specific data. |
| Breastfeeding | Topical application results in minimal systemic absorption; unlikely to pose risk to nursing infant. Avoid application to breast area to prevent infant ingestion. |
■ FDA Black Box Warning
None
| Common Effects | Vaginal burning |
| Serious Effects |
Hypersensitivity to tioconazole or any component of the formulation
| Precautions | For external use only; avoid contact with eyes and mucous membranes, Discontinue if irritation or sensitivity occurs, Not for use in nail or scalp infections |
| Food/Dietary | No clinically significant food interactions. Avoid concurrent alcohol; no specific restriction beyond general healthy diet. |
Loading safety data…
| Lactation Rating |
| L2 |
| Teratogenic Risk | Tioconazole is classified as FDA Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects were observed at doses up to 20 mg/kg/day (approximately 0.2 times the human vaginal dose based on body surface area). However, increased fetal resorptions and delayed ossification occurred at maternally toxic doses. First trimester: insufficient human data. Second and third trimesters: minimal systemic absorption limits risk, but avoid unless clearly needed. |
| Fetal Monitoring | No specific monitoring required beyond routine prenatal care. For pregnant patients, monitor for signs of vaginal irritation or hypersensitivity reactions. If used near term, observe newborn for any signs of local irritation or adverse effects. |
| Fertility Effects | No studies have been conducted on the effect of tioconazole on fertility. Based on its minimal systemic absorption and short duration of use, it is unlikely to impair fertility in women or men. |
| Clinical Pearls | Tioconazole is an imidazole antifungal used topically for vulvovaginal candidiasis. Single-dose 6.5% ointment is as effective as 3- or 7-day regimens. Warn patients about potential local burning or irritation. Avoid use during menstruation; treat after menses. Consider alternative diagnosis if no improvement in 3 days. |
| Patient Advice | Use the applicator to insert the ointment high into the vagina at bedtime. · Complete the full course even if symptoms improve. · Avoid sexual intercourse during treatment to prevent reinfection. · Do not use tampons, douches, or other vaginal products during therapy. · Discontinue and contact doctor if severe irritation or allergic reaction occurs. · May cause mild burning or itching; this usually resolves with continued use. |